Cantor Fitzgerald Comments on Scholar Rock FY2025 Earnings

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share (EPS) estimate for Scholar Rock down to ($3.41), from a previous estimate of ($3.14).
• Scholar Rock's latest quarterly report showed an EPS of ($0.98), missing consensus estimates by ($0.32).
• The stock has received multiple ratings and price targets from analysts, including a "strong-buy" from Raymond James with a price objective of $53.00.

Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) - Stock analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for Scholar Rock in a research note issued on Thursday, August 7th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earnings per share of ($3.41) for the year, down from their prior forecast of ($3.14). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($2.42) per share. Cantor Fitzgerald also issued estimates for Scholar Rock's FY2026 earnings at ($2.93) EPS.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.32). During the same quarter in the prior year, the business posted ($0.60) earnings per share.

Several other research firms have also recently issued reports on SRRK. Lifesci Capital upgraded shares of Scholar Rock to a "strong-buy" rating in a report on Tuesday, June 3rd. Raymond James Financial set a $53.00 target price on shares of Scholar Rock and gave the stock a "strong-buy" rating in a report on Wednesday, July 30th. Wedbush restated an "outperform" rating and set a $50.00 target price on shares of Scholar Rock in a report on Wednesday, June 18th. Finally, BMO Capital Markets decreased their price objective on shares of Scholar Rock from $57.00 to $45.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Scholar Rock has a consensus rating of "Buy" and a consensus target price of $45.14.

Scholar Rock Stock Up 2.4%

Shares of Scholar Rock stock traded up $0.74 during trading on Monday, reaching $32.20. The company had a trading volume of 1,224,470 shares, compared to its average volume of 1,225,593. The company has a market cap of $3.10 billion, a price-to-earnings ratio of -11.07 and a beta of 0.48. Scholar Rock has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The firm's fifty day moving average is $35.78 and its 200-day moving average is $34.28. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.33 and a current ratio of 6.33.

Institutional Investors Weigh In On Scholar Rock

A number of hedge funds have recently made changes to their positions in SRRK. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Scholar Rock by 42.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 135,231 shares of the company's stock valued at $5,845,000 after buying an additional 40,436 shares during the period. GAMMA Investing LLC boosted its stake in Scholar Rock by 3,824.9% in the first quarter. GAMMA Investing LLC now owns 30,928 shares of the company's stock worth $962,000 after buying an additional 30,140 shares in the last quarter. Blackstone Inc. purchased a new stake in shares of Scholar Rock during the fourth quarter valued at approximately $910,000. Raymond James Financial Inc. purchased a new stake in shares of Scholar Rock during the fourth quarter valued at approximately $2,625,000. Finally, California State Teachers Retirement System boosted its stake in shares of Scholar Rock by 30.1% during the fourth quarter. California State Teachers Retirement System now owns 56,269 shares of the company's stock valued at $2,432,000 after purchasing an additional 13,015 shares during the period. 91.08% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Joshua Reed sold 5,400 shares of the firm's stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $29.72, for a total value of $160,488.00. Following the completion of the transaction, the director owned 15,732 shares in the company, valued at $467,555.04. This trade represents a 25.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mo Qatanani sold 24,066 shares of the firm's stock in a transaction that occurred on Tuesday, July 8th. The stock was sold at an average price of $34.44, for a total transaction of $828,833.04. Following the sale, the insider directly owned 115,495 shares of the company's stock, valued at approximately $3,977,647.80. This trade represents a 17.24% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 93,654 shares of company stock valued at $3,101,811. Company insiders own 13.30% of the company's stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.